Some preclinical studies have supported the idea that COX-2 inhibitors in combination with radiotherapy provides potential benefits for patients with advanced NSCLC.53,54 However, there is no clear conclusion on the survival rate because we examined only one relevant study.55 A clearer conclusion must be made with additional high-quality articles related to radiotherapy combined with celecoxib. Here, PTGS2 is linked to non-small cell lung carcinoma.